Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gaush MeditechFRA:F7Y +0.93%61 Return-on-Tangible-Asset is 8.96% as of Dec. 2025, which is 46% above its 10-year median of 6.13. GuruFocus rates FRA:F7Y with a GF Score™ of 61/100 and a GF Value™ of €1.37 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Gaush Meditech ranks better than 74.39% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Gaush Meditech's annualizedNet Income for the quarter that ended in Dec. 2025 was €14.1 Mil. Gaush Meditech's average total tangible assets for the quarter that ended in Dec. 2025 was €157.5 Mil. Therefore, Gaush Meditech's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 8.96%.
The historical rank and industry rank for Gaush Meditech's Return-on-Tangible-Asset or its related term are showing as below:
FRA:F7Y'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -24.18 Med: 6.13 Max: 10.92
Current: 7.36
During the past 7 years, Gaush Meditech's highest Return-on-Tangible-Asset was 10.92%. The lowest was -24.18%. And the median was 6.13%.
FRA:F7Y's Return-on-Tangible-Asset is ranked better than 74.39% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 0.62
vs FRA:F7Y: 7.36
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Gaush Meditech Return-on-Tangible-Asset Related Terms
Gaush Meditech Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Gaush Meditech's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:F7Y vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Gaush Meditech's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gaush Meditech Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gaush Meditech's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Gaush Meditech's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 8.96% mean?
Gaush Meditech (FRA:F7Y) has a Return-on-Tangible-Asset of 8.96% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Gaush Meditech and its competitors. This is 46% above median its historical median of 6.13. According to the industry distribution chart, Gaush Meditech ranks #219 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 25.6%.
Is Gaush Meditech's Return-on-Tangible-Asset too high?
Gaush Meditech's current Return-on-Tangible-Asset of 8.96% is 46% above median its 10-year median of 6.13. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.62. Gaush Meditech's value of 8.96% is 1345.2% above this industry median. Based on the distribution chart, Gaush Meditech ranks #219 out of 855 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Gaush Meditech has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gaush Meditech's Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Gaush Meditech ranks #219 out of 855 companies for Return-on-Tangible-Asset. This puts Gaush Meditech in the upper half of its industry. The industry median Return-on-Tangible-Asset is 0.62. Gaush Meditech's value of 8.96% is 1345.2% above this benchmark. While the company's 10-year median is 6.13 vs. the industry median of 0.62, Gaush Meditech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.62, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gaush Meditech's current Return-on-Tangible-Asset of 8.96% is 1345.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Gaush Meditech and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gaush Meditech's current Return-on-Tangible-Asset is 8.96%, which is 46% above median its own 10-year median of 6.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gaush Meditech stock overvalued right now?
Based on GuruFocus' analysis, Gaush Meditech (FRA:F7Y) is currently considered Possible Value Trap. The stock's GF Value™ is €1.37, compared to a current price of €0.54 — trading 60.6% below its estimated fair value. The current Return-on-Tangible-Asset is 8.96%, which is 46% above median its 10-year median of 6.13 and 1345.2% above the Medical Devices & Instruments industry median of 0.62. Gaush Meditech's overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Gaush Meditech (FRA:F7Y), the current Return-on-Tangible-Asset is 8.96% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gaush Meditech (FRA:F7Y) Overvalued in 2026?
Based on GuruFocus' analysis, Gaush Meditech stock appears to be undervalued.
The current stock price of €0.54 is trading 60.6% below its estimated GF Value™ of €1.37.
GuruFocus considers Gaush Meditech to be Possible Value Trap.
Key valuation signals for FRA:F7Y:
Return-on-Tangible-Asset: 8.96% (46% above median its 10-year median of 6.13)
GF Value™: €1.37 vs. price of €0.54 (60.6% below fair value)
Industry Position: 1345.2% above the Medical Devices & Instruments median (#219 of 855)
No single metric tells the full story. See the FRA:F7Y stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gaush Meditech Ltd is a provider of a broad spectrum of manufacture and sale ophthalmic medical devices and provision of technical services. The segments of the company include Proprietary products segment that derives maximum revenue, develops and produces surgical equipment and related supporting software, intra-optical lens, ophthalmic disease diagnosis and treatment equipment and related supporting consumables independently; Distribution products segment sells multi-function diagnostic equipment, ocular fundus diagnosis, surgical and treatment equipment and related supporting consumables produced by ophthalmic medical equipment manufacturers; Technical services segment provides warranty services, maintenance services and other related consumables; and Others segment.
61GF Score
Get the complete analysis for FRA:F7Y
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:F7Y has been successfully added to your 
